U.S., Sept. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07185490) titled 'CT103d for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma' on Sept. 05.
Brief Summary: This study is a single-center, open-label, dose-exploration trial designed to evaluate the tolerability and safety of different doses of CT103d in patients with relapsed/refractory plasma cell neoplasms, determine the recommended dose of CT103d, and assess its pharmacokinetic and pharmacodynamic characteristics. Additionally, the study will preliminarily observe the efficacy of the investigational drug in a small sample of subjects with relapsed/refractory multiple myeloma.
Study Start Date: Sept. 15
Study Type: INTERVENTIO...